PMID: 9849822 Reported Bone-growth effects (preclinical) Longitudinal bone-growth rate increase without IGF-1 elevation (15-day rat study) Johansen and colleagues (Growth Horm IGF Res 1999) reported that adult female rats dosed with ipamorelin for 15 days showed a dose-dependent increase in longitudinal bone-growth rate (from 42 m/day in controls to 4452 m/day) with concurrent body-weight gain
Make sure to measure dosing solutions with precision, documenting both the concentration and volume used
The injectable version, our BPC 157 Peptide, is often used for targeted research, while oral formulations like our BPC 157 Capsules are typically studied for their potential benefits within the gastrointestinal tract and for systemic effects originating from gut absorption
Consistency and duration matter more than escalation
Theoretically, the two compounds target completely different receptor systems (amylin receptors for cagrilintide, GLP-1/GIP/glucagon for retatrutide), which suggests they could work synergistically without receptor overlap
Foundational paper outlining glutathiones antioxidant and cellular roles
